Pramiracetam: what does this study show?
Double-blind placebo-controlled research in males with brain injury used pramiracetam sulphate 400 mg three times daily. The abstract does not state sample size or the controlled-phase duration.
Memory, especially delayed recall, improved compared with placebo. Improvement persisted during an 18-month open-treatment extension and one month after discontinuation.
The extension was open treatment. The sparse abstract does not establish healthy-person benefit or a comprehensive safety profile.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
The extension was open treatment. The sparse abstract does not establish healthy-person benefit or a comprehensive safety profile.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.